Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Keros Therapeutics Q2 EPS $(0.76) Beats $(1.11) Estimate, Sales $18.168M Beat $2.767M Estimate

Author: Benzinga Newsdesk | August 06, 2025 03:45pm
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.11) by 31.78 percent. This is a 39.2 percent increase over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $18.168 million which beat the analyst consensus estimate of $2.767 million by 556.71 percent. This is a 49.00K percent increase over sales of $37.000 thousand the same period last year.

Posted In: KROS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist